Media

Media

May 26, 2026
Dermatology Times
Soquelitinib Demonstrates Efficacy in Atopic Dermatitis After Systemic Failure

May 21, 2026
Dermatology Times
ITK Inhibition With Soquelitinib Yields Sustained Skin Clearance Up to 90 Days Off Therapy

January 28, 2026
BioTech TV
Corvus Pharma CEO Richard Miller fields follow-up questions about last week's atopic dermatitis data for the ITK inhibitor soquelitinib

December 8, 2025
BioTech TV
ASH 2025: Corvus CEO Richard Miller believes that ITK inhibitors can have the same broad impact on T-cell diseases as BTK inhibitors have had on B-cell diseases - he would know